about
Dual action of antimonial drugs on thiol redox metabolism in the human pathogen Leishmania donovaniEfficacy of anti-leishmania therapy in visceral leishmaniasis among HIV infected patients: a systematic review with indirect comparisonDiagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH).Liposomal amphotericin B and leishmaniasis: dose and responseThe impact of human immunodeficiency virus (HIV) co-infection on the economic burden of cutaneous leishmaniasis (CL) in Brazil and potential value of new CL drug treatmentsUpdate in the treatment of cutaneous leishmaniasis.Lower trypanosomatids in HIV/AIDS patients.Parasitic central nervous system infections in immunocompromised hosts: malaria, microsporidiosis, leishmaniasis, and African trypanosomiasis.The relationship between leishmaniasis and AIDS: the second 10 yearsThe triterpenoid fraction from Trichosanthes dioica root exhibits in vitro antileishmanial effect against Leishmania donovani promastigotes.HIV-1/parasite co-infection and the emergence of new parasite strains.Recurrences of visceral leishmaniasis caused by Leishmania siamensis after treatment with amphotericin B in a seronegative child.Successful use of miltefosine and sodium stibogluconate, in combination, for the treatment of an HIV-positive patient with visceral leishmaniasis: a case report and brief review of the literature.Five-year retrospective Italian multicenter study of visceral leishmaniasis treatment.Drug-resistant microorganisms with a higher fitness--can medicines boost pathogens?Impact of a co-factor on the dynamics of Leishmania donovani infection: does HIV infection encourage the recurrence of visceral leishmaniasis following post-kala-azar dermal leishmaniasis?Visceral leishmaniasis in immunosuppressed Caucasian patient.Comparative Assessment of Induced Immune Responses Following Intramuscular Immunization with Fusion and Cocktail of LeIF, LACK and TSA Genes Against Cutaneous Leishmaniasis in BALB/c Mice.HIV/AIDS-associated visceral leishmaniasis in patients from an endemic area in Central-west Brazil.Clinical and epidemiological features of visceral leishmaniasis and HIV co-infection in fifteen patients from Brazil.Pharmacological inhibition of p110δ subunit of PI3K confers protection against experimental leishmaniasis.Limited effectiveness of high-dose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence.Liposomal amphotericin B for visceral leishmaniasis in human immunodeficiency virus-coinfected patients: 2-year treatment outcomes in Bihar, India.Immunomodulatory Therapy of Visceral Leishmaniasis in Human Immunodeficiency Virus-Coinfected Patients.Speciation of Antimony(III) and Antimony(V) in Bottled Water by Hydride Generation-Inductively Coupled Plasma Optical Emission SpectrometryThe Burden of Visceral Leishmaniasis in India: Challenges in Using Remote Sensing and GIS to Understand and Control
P2860
Q28271918-0B2FF6D6-AB3B-446F-A111-0FEECA66D2F9Q28487597-CC329E38-2683-4C40-A6A4-3292CB024552Q30275257-241E7776-15DB-4F8E-AC84-EB4E6BF7910AQ33929854-0FB9C0EC-1B6A-4EFD-AFD8-127A98014536Q34138468-037D5796-FC25-412A-9B3C-3FB18FAF798CQ34421618-E9765BC0-7020-46BE-AD93-D20B0B44CD95Q35609030-CB12E43F-6738-41D1-8F40-CE452EBDFB79Q36328956-F5F98B32-21B8-46E2-BEA1-28A597D58608Q36538814-1407CC4A-E107-4D7C-8931-8A50FBEE0C40Q36938030-953667B8-9C57-456D-82B9-87862A17C9AAQ37120966-794AA438-486C-464E-AAA3-A46AFB84F35BQ37456147-AF44DEFB-27F9-4399-9658-B6893AC11E68Q37543667-85CD8253-D1DD-4B8F-911D-B007E94733C1Q37544514-122E61C6-A1BE-44F6-B5CF-3AE6CFACA14AQ38040818-30137D88-705D-414C-834C-CAB48688F105Q39293405-5E2F8758-C533-45F3-A380-F728C7BDAB10Q39529489-C2204B1D-30F5-400E-BB66-E35D6735506DQ40105761-9834D21B-DF34-4BD3-BDBA-0DDFEFADB3F5Q40348811-6DFD1FAE-2CC0-4B6D-94E0-644FF28D686BQ40383495-9CA60387-6126-40D3-A54F-CF6C8B52955AQ40401733-EDC30AAA-A093-4EDB-80A9-4B4780B2B99BQ44895818-24850990-79D6-444B-9499-4A62163E1D77Q45363637-AE47446C-F510-4312-9FF4-4C89952E5C20Q47548487-5E427C0B-C80E-49F1-8E5A-B7778FBDA9F2Q58131052-202B2CA5-85D2-4D40-A76B-6C31570A3A8AQ58998296-6D521E67-1BB7-4905-9DB9-7F6245728E6E
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
2003年论文
@zh
2003年论文
@zh-cn
name
Treatment of leishmaniasis in HIV-positive patients.
@ast
Treatment of leishmaniasis in HIV-positive patients.
@en
type
label
Treatment of leishmaniasis in HIV-positive patients.
@ast
Treatment of leishmaniasis in HIV-positive patients.
@en
prefLabel
Treatment of leishmaniasis in HIV-positive patients.
@ast
Treatment of leishmaniasis in HIV-positive patients.
@en
P2860
P1476
Treatment of leishmaniasis in HIV-positive patients.
@en
P2093
P2860
P304
P356
10.1179/000349803225002606
P478
97 Suppl 1
P577
2003-10-01T00:00:00Z